Skip to main content
. 2018 Nov 27;8:17418. doi: 10.1038/s41598-018-35603-0

Table 1.

Subject demographics.

Characteristic MS participant (n = 24) Control (n = 24)
Age range (yrs) 40.7 ± 8.5 43.3 ± 16.4
EDSS 2.4 ± 1.3
Disease duration (yrs) 9.3 ± 6.6
Treatment (n)
  • Naïve 1
  • OFF > 3 months 4
  • Interferon beta-1b 2
  • Interferon beta-1a 3
  • Glatiramer acetate 2
  • Natalizumab 4
  • Fingolimod 8